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Abstract Increasing reported complications associated
with permanent soft tissue ﬁllers have led the national
medical societies and governmental institutes in Europe to
send out warnings regarding their use. Regulation and
legislation for the introduction of new products and the use
of existing products are necessary to guarantee patient
safety.
Keywords Complications  Permanent soft tissue ﬁllers 
Safety
In 2006, the Dutch Authority on Safety Issues in Health-
care (IGZ) sent out a warning regarding the use of per-
manent soft tissue ﬁllers. This warning was sent at the
advice of the Governmental Institute on Health and Envi-
ronment (RIVM), which has produced an elaborate report
on the safety of permanent soft tissue ﬁllers [1]. In this
report, the use of Artecoll, Liquid Silicone, Bio-Alcamid,
Aquamid, Dermalive, and New Fill/Sculptra in the Neth-
erlands is thoroughly evaluated and criticized.
Additionally, at about the same time, the International
Committee for Quality Assurance, Medical Technologies
and Devices in Plastic Surgery (IQUAM) sent out a
similar warning [2]. The IQUAM, an international pro-
fessional medical and scientiﬁc organization committed to
the surveillance of existing and new medical technolo-
gies, devices, and procedures in plastic surgery, is dedi-
cated to their safe use and to the guarantee of patients’
safety.
Both of the aforementioned reports are the result of a
growing knowledge on the adverse effects of permanent
soft tissue ﬁllers. This report aims to share the knowledge
of these two reports with the international aesthetic surgery
community reading Aesthetic Plastic Surgery.
Published Reports
The governmental and legal regulation of soft tissue ﬁllers
varies widely from country to country. Approval often is
gained after a short-term evaluation period in a limited
clinical setting (only a few months).
The RIVM Report
The Dutch RIVM report clearly stated that the current
published clinical data on permanent soft tissue ﬁllers are
insufﬁcient for drawing conclusions concerning their
safety in the long term. To date, described complications
with these ﬁllers are almost all related to case studies,
retrospective data, or both, from which it is not possible
to establish whether the cause of these complications are
product related or a consequence of inexperienced treat-
ment. Therefore, it is recommended that each product and
its treatment technique be evaluated in prospective clin-
ical studies assessing both the short- and long-term
results.
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can be ruled out, not even when the product is administered
skillfully by an experienced physician. The risk of com-
plications however increases if the physician has insufﬁ-
cient knowledge of the product and the way to use it
properly (e.g. the injection technique and preparation of the
product) or has insufﬁcient knowledge of the speciﬁc
indication for the use of the product [3–6].
The RIVM therefore recommends that permanent ﬁllers
may be used only by properly trained physicians with a
relevant medical specialization, such as plastic surgeons
and dermatologists who have demonstrable knowledge and
experience of the product and its applications.
The IQUAM Report
The IQUAM report stresses that all permanent soft tissue
ﬁllers are associated with risks of infection and granuloma
formation, which may lead to major disﬁguration. The risks
depend on the nature of the soft tissue ﬁller, its volume
used, the depth of injection, the site of injection and many
other factors. Appropriate guidelines often are lacking, and
as the clinical use of permanent soft tissue ﬁllers expands
rapidly, there is considerable overlap in application. More
choices demand greater clinical judgment and continuing
clinical trials to highlight the differences, the safety, the
efﬁcacy, and the evolution of the use of these materials.
Substantial biochemical and biophysical differences exist
between commercially available soft tissue ﬁllers as well as
variations in their substance and purity. Therefore, most of
these products have not stood the test of time and thus
should still be considered experimental.
Clinical studies on new permanent soft tissue ﬁllers
offered by manufacturers are mostly not sufﬁcient to pre-
dict the incidence of late reactions. Therefore, continued
long-term postmarketing surveillance by both manufac-
turers and notiﬁed bodies is essential. Physicians should
remain alert to detect late adverse events and report them
immediately to the competent authorities. It is the latter’s
responsibility to report regular updates to both patients and
users on the latest insights concerning risks and adverse
events with newly introduced soft tissue ﬁllers.
The supply of ﬁllers should be limited to trained phy-
sicians only. Therefore, IQUAM urges governments to pass
legislation to protect patients from unduly trained physi-
cians and non-medical personnel injecting materials for
various indications. The current position of IQUAM is to
sustain the ban on the use of liquid silicone as a permanent
soft tissue ﬁller in aesthetic plastic surgery.
Relatively high volumes of injected permanent ﬁllers,
especially hydrogels, are reported to cause severe irre-
versible damage and therefore have generated substantial
concern. After reviewing the accumulated reports, IQUAM
recommends that permanent hydrogels not be used due to
the high incidence of severe complications.
Based on past experience IQUAM states that Confor-
mite ´ Europe ´ennemarks (CE) and U.S. Food and Drug
Administration (FDA) approvals are required steps in
establishing the safety of medical devices, but are not
necessarily sufﬁcient. Post marketing surveillance reveal-
ing new adverse information should lead to reconsideration
of the approval status.
Conformite ´ Europe ´enne and U.S. Food and Drug
Administration
Arteﬁll, a permanent ﬁller composed of polymethylmeth-
acrylate microspheres and bovine collagen, received pre-
market approval by the FDA based on a prospective study,
among other things [7, 8]. The ‘‘conditions of approval’’
include a postapproval study for the monitoring of long-
term adverse effects.
The Dutch Society for Plastic and Reconstructive Sur-
gery, in collaboration with the Dutch Society for Aesthetic
Plastic Surgery, has deﬁned guidelines on the use of per-
manent soft tissue ﬁllers in the Netherlands. Presented in
2006 to the Dutch Authority on Safety Issues in Healthcare
(IGZ) [9, 10], these guidelines were incorporated into the
RIVM report. Currently, these guidelines are of importance
in several lawsuits regarding malpractice in the soft tissue
ﬁlling business. The Swiss Society for Plastic Surgery has
banned the use of permanent soft tissue ﬁllers since 2004
[11]. International Confederation for Plastic Reconstructive
and Aesthetic Surgery (IPRAS) Secretary and former
president of the German Society for Plastic Surgery, Marita
Eisenmann Klein has sent out a serious warning on the use
of permanent soft tissue ﬁllers because of the growing
number of reports on complications of permanent ﬁllers
[12].
Conclusion
We believe that, to date, the introduction and use of most
permanent soft tissue ﬁllers have in no way been subject to
properly designed prospective scientiﬁc research and
therefore should still be considered as fully experimental.
The lack of properly designed prospective studies is
impressive and undesirable. With the ‘‘oath of Hippo-
crates’’ in mind: ‘‘we should not harm our patients,’’ as
physicians, we should be fully aware of our responsibility
to treat our patients carefully and responsible. The further
introduction of these materials on the international markets
should be carried out very cautiously to guarantee the
safety of our patients.
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